A new personalized vaccine designed for one of the deadliest forms of brain cancer is giving scientists fresh hope that the immune system may one day help patients fight back against a disease that has long been considered almost impossible to treat successfully.
Researchers from Washington University School of Medicine and other institutions have reported encouraging early results from a small clinical trial involving patients with glioblastoma, a very aggressive and fast-growing brain cancer.
The findings were published in the journal Nature Cancer.
Glioblastoma is one of the most dangerous cancers doctors treat. In the United States, it affects about four out of every 100,000 people. Even with surgery, radiation, and chemotherapy, the disease almost always comes back.
Most patients survive only a short time after diagnosis because the cancer spreads quickly through the brain and is extremely difficult to remove completely.
The disease is also difficult because it can hide from the immune system. Normally, the immune system is designed to recognize and destroy harmful cells. But glioblastoma has developed ways to avoid detection, allowing the tumor to continue growing even while the body’s natural defenses are present.
Scientists have spent years trying to create treatments that can teach the immune system to attack glioblastoma more effectively. Some immunotherapy approaches have shown promise in early testing, but many have failed to stop the cancer from returning.
The new study tested a different idea: creating a vaccine customized for each individual patient.
Every tumor is slightly different because cancer cells carry unique mutations and abnormal proteins. The researchers developed a vaccine that teaches the immune system to recognize proteins found only in a patient’s own tumor cells.
The treatment uses specially engineered DNA molecules. These molecules carry instructions that help the immune system identify and attack the cancer. Researchers selected up to 40 unique cancer proteins from each patient’s tumor, which is far more than previous cancer vaccines had targeted.
Scientists hoped that attacking many targets at once would make it harder for the cancer to escape immune detection.
Lead researcher Tanner Johanns from Washington University School of Medicine explained that glioblastoma tumors can change over time.
If a treatment attacks only one or two targets, the tumor may survive by simply losing those targets. By training the immune system to recognize many different proteins, the vaccine may create a stronger and broader immune attack.
Another challenge with glioblastoma is that it is considered a “cold” tumor. This means the area around the tumor prevents the immune system from becoming active. The researchers believe the vaccine may help transform these cold tumors into “hot” tumors that are easier for immune cells to attack.
The vaccine used in the trial is called GNOS-PV01. Scientists created it using advanced computer programs that identified proteins unique to each patient’s cancer. Researchers Obi Griffith and Malachi Griffith from Washington University helped develop the system used to select these tumor proteins.
The clinical trial involved nine adults who had recently been diagnosed with glioblastoma. All patients were treated at the Siteman Cancer Center.
After surgery to remove as much of the tumor as possible, doctors created a personalized vaccine for each patient during recovery and radiation treatment. Vaccine injections began about 10 weeks after surgery.
Patients received injections every three weeks for nine weeks and then every nine weeks afterward if they continued participating in the study.
The results were encouraging for such an aggressive disease.
Researchers found that nearly all participants showed signs that their immune systems were responding to the vaccine. Only one patient failed to show an immune response, and that patient was taking a steroid drug that suppresses immune activity.
About one-third of the patients had no cancer progression six months after surgery. About two-thirds survived for at least one year, and two-thirds were still alive after two years. Historically, survival rates for glioblastoma are usually much lower.
One patient remains alive and cancer-free almost five years after diagnosis, something considered extremely rare for this disease.
Researchers say the study is still very small and only represents an early-stage phase 1 trial. Larger studies involving many more patients will be needed before doctors can know how well the vaccine truly works.
The study was also mainly designed to test safety rather than prove effectiveness. Scientists reported that the vaccine caused no serious side effects, which is an important first step in cancer treatment research.
The findings are exciting because they suggest personalized vaccines may someday become an important part of brain cancer treatment. Instead of using a single treatment for every patient, doctors may eventually be able to design therapies based on the exact genetic makeup of each individual tumor.
The research also highlights how cancer treatment is increasingly moving toward precision medicine, where therapies are customized for each person rather than using a one-size-fits-all approach.
Still, important questions remain unanswered. Researchers do not yet know whether the vaccine alone is responsible for the longer survival seen in some patients. Because the trial included only nine people and did not compare patients directly against a control group, larger studies are necessary.
Scientists also want to know whether combining the vaccine with other immunotherapies or cancer treatments could improve outcomes even further.
Even with these limitations, the study offers rare optimism in a disease where treatment advances have historically been slow. Glioblastoma remains one of the deadliest cancers, and any progress is considered highly significant.
The results suggest that personalized cancer vaccines may help the immune system recognize brain tumors more effectively and potentially extend survival for some patients.
While much more research is still needed, the findings represent an important early step toward more targeted and individualized treatment for glioblastoma.
If you care about cancer, please read studies that low-carb diet could increase overall cancer risk, and new way to increase the longevity of cancer survivors.
For more health information, please see recent studies about how to fight cancer with these anti-cancer superfoods, and results showing daily vitamin D3 supplementation may reduce cancer death risk.
Source: Washington University School of Medicine.
